PMI’s FDA-approved SynCardia STAH is promising, but adoption and revenues lag; cash burn and dilution weigh. Read the full ...
Robert Half trades at an 80% discount from its 2022 peak, despite operating cash flows declining only 40%. See why I rate RHI ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback